Home
overview

Controlled release remains one of the most important innovate areas in pharma, with revenues set to dramatically increase to 2020. Recent advances in drug delivery systems have created the perfect mix for opportunities in the field.

SMi is proud to present its 11th annual controlled release conference, held in central London on the 12 & 13 March 2014. The meeting will continue in a long tradition of critically acclaimed speakers who are pioneers in their field. This event offers you a unique opportunity to keep up to date with the latest in technologies and methods such as the diffusion of nanomaterials through biological and non-biological gels.
 

Discover the very latest developments in this innovative and booming industry
Investigating structure-activity relationships of siRNA nanoparticles
Challenges of pre-clinical gastro-retentive dosage form development
Meet, share knowledge and do business with key industry professionals, leading
academics and healthcare representatives
 

Business Reasons to Attend:

• Controlled Release 2014 will cover the GI tract in oral formulation design and oral drug delivery to the Colon with Luigi ‘Gino’ Martini joining the speaking panel to give an industry perspective on oral product development programs

• Join Joel Richard, Vice President Peptides, CMC and Engineering at Ipsen as he gives an overview of the present status and future outlook of peptide delivery. A drug market that is estimated at $15 billion

• A professional environment with expert speakers from leading pharma companies including GlaxoSmithKline, Johnson & Johnson, Ipsen and Novartis available to network and help build upon market intelligence to further business strategies

• Designing dosage forms that allow for more effective drug delivery and release is critical for success in both the clinic and marketplace. Patrick Crowley, Author and Editor of ‘Controlled Release in Oral Drug Delivery’ will demonstrate how to attain target performance profiles for dosage form design
 

You should attend this event if you are a Director, Area head, Chief Executive, CSO, or Vice President within the pharmaceutical or healthcare industry with responsibilities in the following areas

  • Nanomedicine
  • Drug Delivery
  • Drug Development
  • Formulation
  • Business Development
  • Product Development
  • Research & Development
  • Global Alliances
  • Technical Sciences / Design
     

3m Healthcare; Adocia; Advalis technologies Srl; Aston University; Bird & Bird; Bristol-Myers Squibb Pharmaceuticals Ltd; Corden Pharma; Critical Pharmaceuticals Limited; Dow Wolff Cellulosics; Glaxo Smith Kline; GlaxoSmithKline; GlaxoSmithKline Research & Development; Hoffmann-La Roche Inc; Imperial College London; IPI (International Pharmaceutical Industry); Ipsen; Isochem; Kingston University; Lubrizol Advanced Materials Europe BVBA; Lubrizol Limited; MEDESIS PHARMA SA; Medicines Control Agency; Medimetrics; Merck & Co. , Inc.; Merck KGaA; Merrion Pharmaceuticals; MHRA; Mundipharma Research Ltd; Nanosight; Norgine Ltd; Novartis; Novartis Pharma; Novartis Pharma AG; Octo Plus; P C A S; Pharmacircle; RiboBio; School of Pharmacy University of Lisbon; Shire Pharmaceuticals; Shire Pharmaceuticals Group Plc; Sigmoid Pharma Limited; Silence Therapeutics AG; Syngenta; Takeda Pharma; Technology Catalysts International UK; UCB; University Of Bath; University Of Greenwich; University Of Helsinki; University of Leeds; University Of Lisbon; University of Nottingham; University Of Porto; University Of Reading; University Of Strathclyde; Xstalbio Ltd;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Howard Stevens

Howard Stevens, Professor, University Of Strathclyde

9:10 Setting Specifications for Controlled Release Products: A Statistically Based Approach

David Elder

David Elder, Externalisation Director, GlaxoSmithKline Research & Development

  • Role of dissolution testing
  • Evolution of pharmacopoeial specifications for dissolution testing
  • Specification requirements;
  • Bio pharmaceutics
  • Sampling intervals
  • IVIVC / No IVIVC
  • ICH Decision Tree
  • Statistical Evaluation;
  • Approach of Sathe (90% confidence ellipses)
  • Box and Whisker plots
  • Interactions with FDA
  •  

    9:50 Overcoming the impact of the GI tract in oral formulation design

    Howard Stevens

    Howard Stevens, Professor, University Of Strathclyde

  • GI tract physiology, pH, motility and dosage form transit
  • Visualisation of dosage forms in man
  • Design of formulations to be independent of patient factors
  • 10:30 Morning Coffee

    10:50 Oral drug delivery technology- the challenges an industrial and academic perspective

    Luigi Martini

    Luigi Martini, Professor of Pharmaceutical Innovation, Kings College London

  • Why are oral drug delivery systems so important to pharmaceutical industry and to medical science?
  • Why is there a paucity of new systems and drug delivery companies investing in drug delivery technology?
  • What are the challenges to their development?
  • What are the possible solutions?
  • 11:30 Best pre-formulation strategies for troublesome compounds in early development

    Duk Soon Choi

    Duk Soon Choi, Vice President Preformulation, Kashiv Pharma

  • Understanding drug like properties of molecules to be successful medicine
  • Strategies in selection of the right molecules for clinics
  • Tools and means to overcome limitations
  • Early toxicology enabling formulation strategies for poorly soluble compounds
  • Amorphous formulation development strategies
  • 12:10 Networking Lunch

    13:30 Approaches to improve bioavailability of drugs topically administered to the eye

    Vitaliy  Khutoryanskiy

    Vitaliy Khutoryanskiy, Reader in Pharmaceutical Materials, University of Reading

  • Anatomical and physiological considerations of ocular route of drug administration
  • Approaches to improve corneal permeability
  • Approaches to improve pre-corneal retention
  • In vitro and in vivo methodologies for testing
  • 14:10 Drug Delivery and Sustained Release. How hard can it be?

    Dr Andrew Naylor PhD MRSC

    Dr Andrew Naylor PhD MRSC, Head of Process Development, Critical Pharmaceuticals Limited

  • Challenges of producing sustained release formulations
  • Using CriticalMix, a novel manufacturing method to overcome the problems
  • Improve compliance by ensuring the final product is easy to use and well tolerated
  • 14:50 Afternoon Tea

    15:10 Latest trends in drug delivery

    Tugrul Kararli

    Tugrul Kararli, President, Founder, Pharmacircle

  • Drug Delivery (DD) technologies and formulations
  • Life Cycle Management
  • Pipeline and products using DD technologies
  • Deals/Acquisitions/Investments
  • Unmet needs and future
  • 15:50 Bacteriophage: from phage therapy to delivery systems of therapeutics in other human diseases

    Amin Hajitou

    Amin Hajitou, Senior Lecturer and Principal Investigator , Imperial College London

  • Bacteriophage-guided gene transfer in gene therapy and DNA vaccine
  • Advantages of using bacteriophage to existing drug delivery systems
  • Bacteriophage as advanced functional biomaterials
  • 16:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Joel Richard

    Joel Richard, Vice President Peptides , IPSEN

    9:10 Peptide Delivery: What Is the Present Status and What Does the Future Hold?

    Joel Richard

    Joel Richard, Vice President Peptides , IPSEN

  • Understanding the importance of peptides  as a fast growing drug class and the prime focus in formulation and delivery
  • Exploring the global picture of peptide delivery  
  • What developments are made currently in the field of injectable sustained release forms of peptides?
  • What is the next generation of peptide delivery? – oral, transdermal, . . .  opportunities
  • Applying Ipsen technology platform to support long acting  peptide formulations - Case Study: Injectable self-assembling lanreotide
  • 9:50 Creating extended half-life peptide therapeutics using AlbudAbsTM

    Oliver  Schon

    Oliver Schon, Group Leader, NBE Profiling & Analysis, Biopharm Innovation, BIOpharm, GlaxoSmithKline

  • Update on the preclinical and clinical data of domain antibody-based drugs that are currently in clinical development
  • Library design, lead discovery process/engineering
  • Selection of formats for improved biological, biophysical and pharmacokinetic properties, focussing on the half-life extension technology platform
  • 10:30 Morning Coffee

    10:50 Defining and Attaining Target Performance Profiles for Dosage Form Design

    Patrick Crowley

    Patrick Crowley, Owner and Founder, Callum Consultancy

  • The Importance of Defining the Target  
  • Novel Molecular Entities
  • Enhancing Performance for an existing indication.
  • Fixed Drug Combinations 
  • Drug Repurposing 
  • Personalised Medicines
  • 11:30 An Investigation of the Polymorphic Transformation of Paracetamol to Develop Solid Dispersions

    Mohammed Maniruzzaman

    Mohammed Maniruzzaman, Research Associate, University Of Greenwich

  • Variable temperature X-ray powder diffraction (VTXRPD) used to exploit suitability as a predictive tool for monitoring the polymorphic transformation of paracetamol (PMOL)
  • PMOL physical mixtures and extruded formulations with polyvinyl caprolactam graft copolymer, Soluplus (SOL) and vinylpyrrolidone-vinyl acetate copolymer grades, VP/VA S630 (VP/VA)
  • The experimental findings
  • 12:10 Networking Lunch

    13:30 Ion Exchange Technology and Applications

    Der-Yang Lee

    Der-Yang Lee, Research Director and Fellow, McNeil/Johnson & Johnson

  • Chemistry and Mechanism of Action
  • Potential Applications and Real World Examples
  • Future Opportunities
     
  • 14:10 Nanoparticles for intestinal controlled release for drugs with poor solubility and poor permeability

    Bruno Sarmento

    Bruno Sarmento, Affilated Reseracher/Assistant Professor, University Of Porto

  • Pharmaceutical nanomaterials
  • Nanomedicine products
  • Opportunities of nanoparticles in the gastrointestinal tract
  • The value of “nano”
  • Nanonization of API’s
  • Formulation of API’s in nanoparticle delivery systems
  • Passive and Active nanoparticle intestinal target
  • 14:50 Design and development of Cross-linked siRNA delivery system Based on Bio-reducible PAA Nanoparticles for Gene Silencing

    Muhammad Danish

    Muhammad Danish, Senior Lecturer, University of Nottingham

  • Non-viral siRNA delivery is considered very promising but suffers from many of the in vivo delivery challenges
  • Linear PAAs (polyamidoamines) based on MBA DMEDA has previously been used for DNA delivery but their potential for siRNA delivery has not been described yet as non-viral polyelectrolyte complexes (PECs)
  • Main aims include formulation and characterization of cross-linked siRNA polyplexes using blend of linear PAA nanoparticles with bio-reducible characteristics
  • These PAA nanoparticles have shown complete incorporation of siRNA during gel electrophoresis, produced discrete, well condensed spheres below 100nm in diameter using DLS and TEM techniques and were stable in high salt (750nm) and serum conditions
  • Cross-linked polyplexes using CY-3 labelled siRNA were efficiently internalized by A-549 and HCT 116 cells with endosomal release functionality
  • A remarkable dose dependent GAPDH gene silencing (>90%) efficiency was observed on mRNA level using RT-qPCR with no toxicity evaluated by MTS and LDH assays
  • 15:30 Afternoon Tea

    15:50 Development and characterization of parenteral in situ gelling chitosan/glucose-1-phosphate depot systems

    Stephanie Supper

    Stephanie Supper, Senior Scientist, Novartis Pharmaceuticals

  • Gelation mechanism of chitosan/polyol-phosphate systems: role of the polyol part
  • Glucose-1-Phosphate as a new gelling agent: characterization of the physico-chemical properties and shelf life of chitosan / glucose-1-phosphate thermogelling solutions
  • In vitro release and in vivo biocompatibility studies
  • 16:30 Solid microparticles from liquid gases: a novel, dense-CO2 - based technology to address oral drug delivery challenges

    Pierandrea Esposito

    Pierandrea Esposito, Associate Director and Co-founder, SiTec PharmaBio

  • Drives for innovation in drug delivery: meeting needs of patient–centric medicine, industrial process simplification and flexibility
  • Dense CO2-based technologies can address challenges in oral drug delivery
  • Variosol® technology case studies: microparticles for improved drug bioavailability; controlled drug release; site-specific delivery
  • Process hybridization: enabling role of dense and liquid gases to improve potential of processes, and expand the range of application
  • 17:10 Chairman’s Closing Remarks and Close of Day Two

    Joel Richard

    Joel Richard, Vice President Peptides , IPSEN

    +

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.